Skip to main content
. Author manuscript; available in PMC: 2009 May 26.
Published in final edited form as: Oncology (Williston Park). 2007 Aug;21(9):1055–passim.

Table 1.

Phase I/II Studies of Cetuximab With Radiation Therapy and Chemotherapy for Rectal Cancer

Study N EBRT Dose Chemotherapy Cetuximab pCR Rate
MSKCC[38] 20 50.4 Gy/1.8 Gy/5.5 wk 5-FU IV CI, 225 mg/m2/d 400 mg/m2 d 1, then 250 mg/m2 weekly 12%
Heibelberg[39] 20 50.4 Gy/1.8 Gy/5.5 wk Irinotecan, 40–50 mg/m2 (weekly) Capecitabine, 400–500 mg/m2 bid 400 mg/m2 d 1, then 250 mg/m2 weekly 7%*
Louvain[40] 40 45 Gy/1.8 Gy/5 wk Capecitabine, 625–825 mg bid 400 mg/m2/1 wk before RT, then 250 mg/m2 weekly during RT 5%
German Multisite Study[41] 60 50.4 Gy/1.8 Gy/5.5 wk Oxaliplatin, 50 mg/m2 (d1, 8, 22, 26) Capecitabine, 500–825 mg/m2 bid 400 mg/m2/1 wk before RT, then 250 mg/m2 weekly during RT 9%
*

1/14 (7%) uT3 patients had a complete pathologic response whereas 4/5 (80%) uT2 patients had a complete pathologic response.

EBRT = external-beam radiation therapy; 5-FU = fluorouracil; MSKCC = Memorial Sloan-Kettering Cancer Center;

pCR = pathologic complete response; RT = radiation therapy.